Cryoport Systems Wins Best Cell & Gene Therapy Supplier Award for Cold Chain Logistics at APCGTEA 2026
Cryoport Systems is pleased to announce that we have been named Best Cell & Gene Therapy Supplier – Cold Chain Logistics at the 2026 Asia-Pacific Cell & Gene Therapy Excellence Awards (APCGTEA).
This recognition carries special meaning as it reflects the voice of the global advanced therapies community. With participation from thousands of industry professionals, the award highlights the confidence placed in Cryoport Systems to manage one of the most critical aspects of therapy delivery: maintaining temperature-controlled integrity across every step of the journey.
Advancing Cold Chain Logistics for Advanced Therapies
The APCGTEA Awards recognize organizations that are shaping the future of cell and gene therapy through innovation, performance, and measurable impact. This year’s honor underscores the strength of Cryoport Systems’ cold chain logistics platform, built to safeguard sensitive materials from research through clinical use and commercialization.
Our approach combines validated shipping systems, real-time monitoring, and global infrastructure designed specifically for advanced therapies. These capabilities help ensure that temperature-sensitive materials arrive in optimal condition, supporting both regulatory compliance and therapeutic efficacy. Our logistics offering is integrated into our greater end-to-end supply chain platform that includes cryopreservation services, BioServices and biostorage, consulting and advisory support, and best-in-class quality and compliance.
We are grateful to those who supported our nomination and contributed their votes. Their confidence reinforces the importance of strong partnerships in advancing the field and ensuring that therapies reach patients safely and efficiently. At Cryoport Systems, our commitment remains focused on supporting the full therapy lifecycle with solutions that reduce risk and improve outcomes. Cold chain logistics continues to play a central role in that mission, particularly as therapies expand into new regions and patient populations.
This recognition serves as both a milestone and a reminder of the responsibility we carry. We are honored to receive this award and remain committed to Enabling the Outcome™ for our clients and the patients they serve.
